Prothena Co. plc (NASDAQ:PRTA) Shares Sold by DCF Advisers LLC

DCF Advisers LLC lowered its position in Prothena Co. plc (NASDAQ:PRTA) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,500 shares of the biotechnology company’s stock after selling 4,000 shares during the period. DCF Advisers LLC’s holdings in Prothena were worth $1,433,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in PRTA. Teacher Retirement System of Texas purchased a new position in Prothena in the fourth quarter valued at about $145,000. Purkiss Capital Advisors LLC purchased a new position in Prothena in the fourth quarter valued at about $149,000. China Universal Asset Management Co. Ltd. increased its holdings in Prothena by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,065 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Prothena in the fourth quarter valued at about $159,000. Finally, Raymond James Financial Inc. purchased a new position in Prothena in the fourth quarter valued at about $182,000. Institutional investors and hedge funds own 97.08% of the company’s stock.

Analysts Set New Price Targets

PRTA has been the subject of a number of research analyst reports. Oppenheimer increased their target price on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. Chardan Capital restated a “buy” rating and set a $40.00 price objective on shares of Prothena in a research report on Friday, February 21st. Bank of America cut their price objective on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Finally, Piper Sandler lifted their price objective on Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Prothena Stock Performance

Shares of PRTA opened at $12.87 on Friday. The stock has a fifty day moving average of $14.33 and a two-hundred day moving average of $15.94. The company has a market capitalization of $692.75 million, a PE ratio of -5.60 and a beta of -0.02. Prothena Co. plc has a fifty-two week low of $11.70 and a fifty-two week high of $26.45.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million. As a group, equities research analysts forecast that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.